Anthem Biosciences — Q2 & H1 FY27 — November 4, 2026

1. Overall Tone of Management

Cautious

Management described Q2 as robust and emphasized strong underlying demand, improved margins and increased RFQs. But the confidence is qualified: Q1 was weak, management said there is “a lot of catching up to do,” and it offered no formal full-year revenue guidance—only that it would “try to deliver double-digit growth.” It also explicitly cautioned against extrapolating Q2’s roughly 50% EBITDA margin.

2. Key Themes from Management Commentary

Q2 rebound after a soft Q1: Q2 revenue was ₹594 crore, versus ₹418 crore in Q1. H1 revenue was ₹1,012 crore; management linked the recovery to customer deliveries and operating leverage.
Margins are strong, but Q2 is not the right run rate: Management attributed the Q2 margin improvement to higher revenue on a largely stable cost base, alongside cost control, yield optimization, and backward integration. It said FY26 margins are sustainable, but not necessarily Q2’s approximately 50% level.
CRDMO remains the growth engine: H1 CRDMO revenue was ₹850 crore, versus ₹162 crore from specialty ingredients. Management says customer demand is strong, though project and delivery timing make quarterly performance lumpy.
Commercial pipeline is advancing: One late-stage molecule was approved in Q2, taking the portfolio to 15 commercial and 9 late-stage molecules. Management sees potential for some late-stage programs to commercialize over the next 18–24 months, while stressing that trial outcomes are uncertain.
New modalities and capacity investment: The company is developing capabilities in peptides, oligonucleotides, RNAi, ADCs, biologics and drug product. Unit 4 remains a major investment, with Phase 1 capex guidance unchanged at ₹1,200 crore.
Supply-chain resilience: Management said it has moved away from reliance on one Chinese vendor over the past 18 months. It reported 75–78% domestic procurement and 20–22% from China, while continuing to develop domestic suppliers.
Customer concentration and confidentiality: The top five customers account for roughly 50% of business and the top ten about 80%. Management declined to identify a newly commercial molecule or provide its peak-sales estimate, citing customer confidentiality.

3. Q&A Analysis

A. Growth recovery, revenue outlook and margins

Analysts asked: Whether Q1’s weakness would reverse, what FY27 growth to expect, how much Q2 growth reflected currency, and whether Q2 margins could continue.
Management said: It expects to “try to deliver double-digit growth,” with revenue catch-up in Q3 and Q4. Currency was range-bound, and management does not track constant-currency growth. FY26 margins are considered sustainable, but management cautioned: “I do not want to say that the 50% number is sustainable.”
Assessment: The recovery case is clear, but the full-year outlook remains unquantified. The Q3/Q4 catch-up is still an expectation, not an achieved outcome.
Historical context: In Q1, management also cited deferred deliveries, a strong order book and confidence in meeting its growth aspirations. It had previously cautioned that quarterly results are lumpy and should be assessed year-on-year.

B. Pipeline conversion and commercial-molecule economics

Analysts asked: What drove the shift from 10 to 9 late-stage molecules and 14 to 15 commercial molecules; when new molecules may ramp; whether new products offset future patent expiries; and how much late-stage work could commercialize.
Management said: One program was approved in Q2. It declined to identify the product or estimate peak sales, but said it is for chronic care and originated with an emerging biotech. Management expects some late-stage programs to move to commercial status over 18–24 months; a few could be approved this financial year, but outcomes depend on trials.
Assessment: Pipeline progress is tangible, but timing and revenue contribution remain uncertain. Management noted that current sole-supplier status for some newer products could change as Big Pharma customers seek second sources.
Historical context: Q1 management described 10 late-stage molecules and said commercialization could be 18–24 months away. Q4 FY26 described four molecules moving to commercial status during FY26, with meaningful ramp-up expected to take two to three years.

C. Capex, Unit 4 and utilization

Analysts asked: Whether the ₹1,200 crore Unit 4 capex plan had changed, what Phase 2 might cost, how the spending would be allocated, and what asset turns to expect.
Management said: Phase 1 guidance remains ₹1,200 crore over two years. Phase 2 is expected to be of similar scale, but management will provide guidance only after board approval. It estimated 30–35% of Phase 1 capex would go to biology, with the balance to chemistry. Current asset turns are about 1.2–1.3x, with an aspiration of 1.5x; Unit 4 will take time to commission, secure approvals and ramp.
Assessment: Phase 1 investment is reaffirmed, but the longer-term capital requirement is still open-ended. Management did not provide a timeline for Unit 4 to reach target asset turns.

D. Demand, biotech funding and customer mix

Analysts asked: Whether improved biotech funding is translating into RFQs, how much business comes from biotech versus Big Pharma, and whether M&A or AI could affect demand.
Management said: RFQs improved in the last quarter, but biotech funding remains a “mixed bag” amid geopolitical uncertainty. It characterized commercial revenue as often originating in biotech programs that later get acquired by Big Pharma. It expects AI-generated drug candidates to create manufacturing work, but could not quantify any FY31 revenue contribution.
Assessment: The RFQ trend is positive but early and not quantified. Management was appropriately cautious about long-range estimates and acknowledged AI’s uncertainty.

E. Geography, concentration and supply chain

Analysts asked: For revenue by geography and business stage, customer concentration, and progress on reducing China sourcing.
Management said: Approximately 84% of revenue is international and 16% domestic; it described Europe as the largest destination and the US as 22–24%. It put CDMO at roughly 85% of business, with about 65% of total business from commercial manufacturing. Top five customers represent about 50% of business and top ten about 80%. Domestic procurement is now 75–78%, with China at about 20–22%.
Assessment: The sourcing update is specific and indicates progress. The high customer concentration is a material exposure. Management cautioned that geography is not a reliable proxy for customer origin or end-market exposure.

F. Specialty ingredients and strategic capabilities

Analysts asked: Whether specialty ingredients’ reduced mix is structural, what growth and margin profile to expect, and which capabilities Anthem is adding.
Management said: It would like specialty ingredients to be at least 20% of sales by year-end, describing the segment as a buffer against CRDMO lumpiness. It said the segment was flat in a strong CDMO quarter, and margins are broadly in line with the overall business. Planned capability additions include biologics manufacturing, fill-finish, oligonucleotides and potential oncology expansion.
Assessment: The 20% mix expectation is not yet supported by H1’s reported mix of about 16%. Management gave no segment-specific margin or detailed growth guidance.

4. Guidance / Outlook

Quantitative guidance

FY27 revenue: No formal full-year guidance. Management said it would “definitely try to deliver double-digit growth.”
Margins: Management said FY26 margin levels are sustainable, but did not endorse Q2’s approximately 50% EBITDA margin as a run rate.
Unit 4 Phase 1 capex: ₹1,200 crore over two years; guidance unchanged. Phase 2 may be of similar scale, but is not approved or formally guided.
Unit 4 investment mix: At least 30–35% expected to go to biology; the rest to chemistry.
Specialty ingredients: Management expects the segment to reach at least around 20% of sales by year-end.
Asset turns: Currently about 1.2–1.3x; aspiration is 1.5x. No specific timeline was given for Unit 4 to reach that level.
Pipeline: Some late-stage molecules may commercialize in the next 18–24 months; management said a few could be approved this financial year, subject to trial outcomes.

Qualitative signals

Underlying demand was described as strong, and management reported increased RFQ inflows in the last quarter.
Management expects revenue catch-up in Q3 and Q4 after a slow Q1.
Unit 4 expansion, investments and required regulatory approvals were described as on track.
Management expects newer modalities and recently commercialized molecules to contribute over time, but did not quantify their likely revenue contribution.

5. Standout Statements

“We will definitely try to deliver double-digit growth.” — Growth ambition, but not formal guidance.
“I do not want to say that the 50% number is sustainable.” — A clear caveat against extrapolating Q2 margins.
“There has been a lot of geopolitical uncertainty, which also makes people uneasy.” — A qualification to the improved RFQ trend.
“At the moment, we enjoy sole-supplier status… but this will change.” — Direct acknowledgment of future competition on newer commercial products.
“We would like the specialty ingredients business to be at least over 20% of our sales.” — A measurable mix objective that remains ahead of current H1 mix.
“We have a lot of catching up to do after the slow quarter in the first quarter.” — Management’s own summary of the FY27 execution burden.

6. Red Flags / Positive Signals

Red flags
– FY27 growth depends on a second-half recovery; no quantified full-year target was provided.
– High customer concentration: top five customers contribute about 50% of business, top ten about 80%.
– Specialty ingredients’ year-end mix goal of at least 20% is above its H1 share of roughly 16%.
– The high Q2 margin was explicitly not characterized as sustainable.
– Future second-supplier competition could reduce the exclusivity of certain commercial programs.
– Unit 4’s eventual returns depend on commissioning, approvals and utilization ramp-up.

Positive signals
– Q2 revenue rebounded sharply from Q1, and management reported improved RFQ inflows.
– One late-stage program advanced to commercial status.
– Management reported reduced China sourcing and substantial domestic procurement.
– Net cash remained positive at ₹1,534 crore at September 30, 2026.
– Management reaffirmed Unit 4 Phase 1 capex and described the project as on track.

7. Historical Comparison & Consistency Analysis

a. Quarter-by-Quarter Tone Evolution

Q4 FY26 — May 20, 2026
– Dominant tone: Optimistic
– Major themes this quarter:
– Strong FY26 finish, including a record Q4 and growth in CRDMO.
– Destocking described as largely behind the company, with restocking expected.
– Investment in Unit 4 and future-ready technologies.
– Confidence in margins, customer stickiness and long-term growth.
– Tone shift vs previous quarter: N/A (baseline)
– What changed: No prior transcript was provided for comparison.

Q1 FY27 — July 22, 2026
– Dominant tone: Neutral
– Major themes this quarter:
– Weak revenue attributed to timing shifts in customer deliveries.
– Management emphasized a 60% order-book position and expected second-half catch-up.
– Unit 4 capex and commissioning timeline reaffirmed.
– Biotech funding recovery, GLP-1 opportunity and customer additions.
– Tone shift vs previous quarter: More Cautious
– What changed:
– The narrative moved from Q4’s strong finish to a “muted” quarter and delivery deferrals.
– Management leaned more heavily on order-book visibility and full-year recovery assurances.
– It avoided specific near-term growth guidance despite maintaining its growth aspiration.

Q2 FY27 — November 4, 2026
– Dominant tone: Optimistic
– Major themes this quarter:
– Q2 rebound and improved margins, attributed partly to operating leverage.
– Strong underlying demand and better RFQ inflows, qualified by geopolitical uncertainty.
– Commercial pipeline progress and investment in newer modalities.
– Unit 4 capex maintained, with returns expected over a longer horizon.
– Tone shift vs previous quarter: More Optimistic
– What changed:
– Management shifted from explaining a weak quarter to highlighting a stronger Q2 and second-half catch-up.
– It became more guarded on margins, explicitly distinguishing Q2’s level from what it considers sustainable.
– Guidance remains limited: management now says it will “try” to deliver double-digit growth, rather than giving a defined target.

Third-last transcript — Not available
– No date or transcript was provided, so the period, tone and quarter-over-quarter shift cannot be established.

Trajectory Summary: Q4 FY26 was strongly upbeat, followed by a more cautious Q1 FY27 as delivery timing created a weak quarter. Q2 brought a clear sequential recovery and renewed confidence, but the core FY27 promise still depends on second-half execution, and management remains careful about both full-year growth and margin expectations.

b. Tracking Past Commitments vs Outcomes

Q1 FY27: “We expect it [Q1] to… only grow” from here.
Expected: Sequential growth from Q1 onward.
What happened: Q2 revenue rose from ₹418 crore to ₹594 crore.
Flag: ✅ Delivered for Q2; Q3/Q4 recovery remains untested.
Q1 FY27: Expected double-digit growth for FY27 and catch-up in Q2–Q4.
Expected: Full-year double-digit growth, with sequential recovery.
What happened: Q2 improved, but management still says it will “try” to deliver double-digit growth; no full-year result yet.
Flag: ⏳ In progress; not yet confirmed.
Q1 FY27: Unit 4 capex and construction schedule.
Expected: ₹1,200 crore Phase 1 capex over FY27–FY28; commissioning around March 2028.
What happened: Capex guidance remains intact; management says expansion and approvals are on track.
Flag: ✅ On track to date; completion not yet due.
Q4 FY26: Specialty ingredients aspired to roughly 20% growth and a separate Unit 4 facility was expected to help reduce capacity competition with CRDMO.
Expected: Stronger specialty growth and improved ability to serve demand independently.
What happened: Management now targets specialty ingredients at around 20% of sales by year-end, but reported the segment as flat in Q2; H1 mix was about 16%.
Flag: ⏳ Not yet demonstrated; the mix target remains a forward expectation.
FY26 growth aspiration: Management discussed a long-term growth aspiration around 20%.
Expected: Approximately 20% revenue growth.
What happened: In Q4, management said revenue growth was about 15% on its cited basis, while EBITDA and PAT growth exceeded 30%.
Flag: ❌ Revenue aspiration missed, partly offset by stronger profit growth.

c. Narrative Shifts

From destocking to delivery timing: Q4 described destocking as largely over and expected restocking. Q1’s weakness was instead framed as customer delivery deferrals; Q2 emphasized recovery and continued demand, while acknowledging geopolitical uncertainty.
From GLP-1 near-term opportunity to broader modality investment: Earlier calls emphasized semaglutide approval and commercialization. The current call did not provide a fresh approval update; discussion focused more on peptides, oligonucleotides, ADCs, RNAi and biology investment.
Greater attention to supply-chain resilience: The current call added quantified procurement exposure—75–78% domestic and 20–22% China—and described a move away from a previously disclosed Chinese vendor.
New emphasis on second-source competition: Management said current sole-supplier status on some products is likely to change as acquired assets attract Big Pharma supplier diversification.
AI remains unresolved: Q1 framed AI use cases as early and vague; Q2 maintained uncertainty but leaned toward AI increasing the number of molecules that require manufacturing.

d. Consistency & Credibility Signals

Overall credibility: Medium

Management has been consistent in describing CRDMO as lumpy and in stressing long-term customer relationships, technology differentiation and capacity investment.
Q1’s promised sequential recovery was followed by a strong Q2 rebound, supporting the timing-shift explanation so far.
However, FY26 revenue growth fell short of the stated aspiration, and FY27 growth remains unquantified despite repeated confidence in a second-half catch-up.
Management is comparatively clear about uncertainty in trials, customer confidentiality, margin sustainability and Unit 4 ramp-up. The main credibility test is whether Q3/Q4 deliver the growth currently being anticipated.

e. Evolution of Key Themes

Demand and growth — Improving, but not yet proven for the year: Q1 was weak; Q2 rebounded and RFQs improved, though funding and geopolitics remain mixed.
Margins — Strong, with more caution on sustainability: Margin discipline is a consistent theme, but Q2 management explicitly declined to call the roughly 50% level sustainable.
Capacity and investment — Stable: Unit 4 Phase 1 capex and timeline have been consistent across calls. Longer-term Phase 2 scale and returns remain uncertain.
Pipeline and commercialization — Improving gradually: Commercial molecules increased from 14 to 15, while late-stage molecules moved from 10 to 9 after one approval. Conversion timelines remain dependent on clinical outcomes and customer ramp-up.
Supply-chain resilience — Improving: Management reports reduced reliance on China and greater domestic procurement.
Specialty ingredients — Mixed: Management continues to position the segment as a stabilizer and targets at least 20% of sales, but H1 mix remains below that level.

f. Additional Insights

The story is increasingly about profitable growth and utilization, not simply adding capacity: management highlighted operating leverage and described Unit 4 returns as a longer-term prospect.
The recovery narrative is partly supported—Q2 rose sequentially—but the remaining FY27 growth target still relies on catch-up in two quarters.
Management’s stronger caution on margin sustainability is a useful counterweight to the strong Q2 headline margin.
New modalities are a long-cycle opportunity rather than a near-term revenue guide: management says capabilities have been built over many years but would not estimate their FY31 contribution.

Anthem Q2 Rebound Leaves FY27 Growth Dependent on Catch-Up